{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:02:23Z","timestamp":1791028943081,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clinbiochem.2012.01.022","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T09:31:38Z","timestamp":1328347898000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Pawel","family":"Szulc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2008.07.006","article-title":"Bone remodelling: its local regulation and the emergence of bone fragility","volume":"22","author":"Martin","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0010","first-page":"1520","article-title":"Biochemical markers of bone turnover in osteoporosis","volume":"Vol. 2","author":"Szulc","year":"2008"},{"issue":"1","key":"10.1016\/j.clinbiochem.2012.01.022_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1272\/jnms.77.4","article-title":"The mechanism of mineralization and the role of alkaline phosphatase in health and disease","volume":"77","author":"Orimo","year":"2010","journal-title":"J Nihon Med Sch"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0020","doi-asserted-by":"crossref","first-page":"18361","DOI":"10.1074\/jbc.M314324200","article-title":"Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro","volume":"279","author":"Ivaska","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI112400","article-title":"Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia comparison with bone histomorphometry","volume":"77","author":"Delmas","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.V73506","article-title":"Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients","volume":"7","author":"Ure\u00f1a","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jbmr.5650080202","article-title":"Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry","volume":"8","author":"Eriksen","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF01622196","article-title":"Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen","volume":"4","author":"Hassager","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00316286","article-title":"The carboxy-terminal pyridinoline crosslinked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy","volume":"54","author":"Hassager","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0055","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.bjc.6603285","article-title":"Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation","volume":"95","author":"Voorzanger-Rousselot","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0060","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin Lab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S8756-3282(95)00174-3","article-title":"Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with depxypyridinoline","volume":"17","author":"Roux","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","article-title":"International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis","volume":"49","author":"Vasikaran","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0075","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00198-007-0407-z","article-title":"Biochemical assessment of bone turnover and bone fragility in men","volume":"18","author":"Szulc","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00198-003-1398-z","article-title":"Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review","volume":"14","author":"Richy","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/8756-3282(96)00110-X","article-title":"Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics","volume":"19","author":"Nyquist","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0095","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jcem.87.2.8232","article-title":"Increased bone resorption in moderate smokers with low body weight: the Minos study","volume":"87","author":"Szulc","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/cs0830375","article-title":"Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing","volume":"83","author":"Eastell","year":"1992","journal-title":"Clin Sci"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type I colagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment","volume":"63","author":"Gertz","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0115","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","article-title":"Mechanism of action of bisphosphonates","volume":"1","author":"Reszka","year":"2003","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1196\/annals.1346.013","article-title":"Regulation of osteoclast differentiation","volume":"1068","author":"Roodman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin\u2014pharmacology in osteoporosis","volume":"10","author":"Henriksen","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0135","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.106.102798","article-title":"An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-flouro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats","volume":"318","author":"Kim","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","article-title":"Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection","volume":"11","author":"Pecherstorfer","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0145","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","article-title":"Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate","volume":"14","author":"Christiansen","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0160","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0165","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0170","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0175","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00198-009-1060-5","article-title":"Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass","volume":"21","author":"Downs","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0185","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0190","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","article-title":"Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":"Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0200","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2004.09.020","article-title":"Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL\/OPG ratio","volume":"36","author":"Kiviranta","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2011.06.014","article-title":"The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking","volume":"49","author":"Leung","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0220","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0225","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0230","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1\u201334) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0240","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0255","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0260","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1359\/jbmr.071012","article-title":"Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate","volume":"23","author":"Arlot","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(99)00076-9","article-title":"A dose-ranging trial of a matrix transdermal 17\u03b2-estradiol for the pevention of bone loss in early postmenopausal women","volume":"24","author":"Delmas","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0275","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0280","first-page":"2197","article-title":"A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women","volume":"85","author":"Prestwood","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0290","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"Tanko","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0300","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0305","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinbiochem.2012.01.022_bb0310","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial","volume":"97","author":"Grey","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0315","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0320","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mienral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0330","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0335","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0340","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","article-title":"Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk","volume":"34","author":"Reginster","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0345","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnasson","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0350","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0355","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00198-008-0827-4","article-title":"Monthly ibandronate suppresses serum CTX-I within 3days and maintains a monthly fluctuating pattern of suppression","volume":"20","author":"Binkley","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0360","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","article-title":"Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate","volume":"14","author":"Christiansen","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0365","first-page":"853","article-title":"Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate","volume":"66","author":"Papapoulos","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0370","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0375","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jbmr.191","article-title":"Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women","volume":"26","author":"Cummings","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clinbiochem.2012.01.022_bb0380","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0385","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0390","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70mg compared to once-weekly risedronate 35mg in the treatment of postmenopausal osteoporosis","volume":"20","author":"Sebba","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0395","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0400","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jc.2005-1712","article-title":"Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis","volume":"91","author":"Bauer","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0405","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-010-1379-y","article-title":"Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24months of treatment with teriparatide","volume":"22","author":"Blumsohn","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0410","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s001980070083","article-title":"Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover","volume":"11","author":"Raisz","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0420","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0425","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0430","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0435","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0440","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S8756-3282(03)00171-6","article-title":"Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study","volume":"33","author":"Sornay-Rendu","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0445","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0450","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0455","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0460","doi-asserted-by":"crossref","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353 555\u2013565.","DOI":"10.1056\/NEJMoa050336"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0465","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1210\/jc.2009-0154","article-title":"Effects of teriparatide retreatment in osteoporotic men and women","volume":"94","author":"Finkelstein","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0470","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00198-008-0825-6","article-title":"Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis","volume":"20","author":"Meunier","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0475","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0480","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0485","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0490","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0495","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0500","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0505","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0510","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0515","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0520","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0525","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0530","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/13697137.2010.537408","article-title":"Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis","volume":"14","author":"Sanad","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0535","unstructured":"Committee for Medicinal Products for Human Use \u2014 guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. European Medicinal Agency CPMP\/EWP\/552\/95 Rev. 2."},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-005-1984-3","article-title":"Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal and in men","volume":"17","author":"Reginster","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0545","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0550","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0555","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","article-title":"Monthly dosing of 75mg risedronate on 2 consecutive days a month: efficacy and safety results","volume":"19","author":"Delmas","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0560","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0565","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal women","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0570","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0575","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0580","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0585","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0590","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0595","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0600","article-title":"Impact of bone turnover markers and\/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0605","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0610","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinbiochem.2012.01.022_bb0615","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0620","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","author":"Saad","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0625","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0501.2010.01965.x","article-title":"Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?","volume":"22","author":"Kwon","year":"2011","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0630","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0635","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0640","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0645","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0650","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tripleo.2010.04.023","article-title":"Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers","volume":"110","author":"Fleisher","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0655","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0660","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0665","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.berh.2009.09.007","article-title":"Monitoring osteoporosis treatment","volume":"23","author":"Compston","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0670","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-006-0218-7","article-title":"Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy","volume":"18","author":"Schousboe","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0675","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0680","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00198-008-0813-x","article-title":"To stop or not to stop, that is the question","volume":"20","author":"Seeman","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0685","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","author":"Glover","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0690","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0695","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00198-009-0974-2","article-title":"Laboratory reproducibility of biochemical markers of bone turnover in clinical practice","volume":"21","author":"Schafer","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0700","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/clinchem\/47.8.1443","article-title":"Interlaboratory variation of biochemical markers of bone turnover","volume":"47","author":"Seibel","year":"2001","journal-title":"Clin Chem"},{"issue":"Suppl. 6","key":"10.1016\/j.clinbiochem.2012.01.022_bb0705","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0710","article-title":"The potential value of monitoring bone turnover markers among women on alendronate","author":"Bell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0715","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0720","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.2002.17.5.826","article-title":"Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study","volume":"17","author":"Garnero","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0725","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/jbmr.467","article-title":"Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women","volume":"26","author":"Tanaka","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0730","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00198-009-0939-5","article-title":"Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study","volume":"21","author":"Gineyts","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0735","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMoa032739","article-title":"Homocysteine as a predictive factor for hip fracture in older persons","volume":"350","author":"McLean","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0740","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1359\/jbmr.061003","article-title":"Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women","volume":"22","author":"Gerdhem","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0745","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1210\/jc.2008-1777","article-title":"Homocysteine levels and risk of hip fracture in postmenopausal women","volume":"94","author":"Leboff","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0750","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM199707243370403","article-title":"Plasma homocysteine levels and mortality in patients with coronary artery disease","volume":"337","author":"Nyg\u00e5rd","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0755","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lab.2005.03.016","article-title":"Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?","volume":"146","author":"Holzer","year":"2005","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0760","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0765","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/or.2011.1194","article-title":"Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma","volume":"25","author":"Fujimoto","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0770","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2337\/dc09-0901","article-title":"Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes","volume":"32","author":"Yamamoto","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0775","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1464-5491.2010.03187.x","article-title":"Thiazolidinediones and fracture risk in patients with type 2 diabetes","volume":"28","author":"Betteridge","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0780","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-011-1778-8","article-title":"Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case\u2013control studies","volume":"23","author":"Wu","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0785","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAD.0b013e32834ed8a7","article-title":"Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study","volume":"26","author":"Hansen","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0790","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0795","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jpsychires.2011.04.005","article-title":"Treatment of a major depression episode suppresses markers of bone turnover in premenopausal women","volume":"45","author":"Aydin","year":"2011","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0800","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir\u2013lamivudine versus tenofovir\u2013emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinbiochem.2012.01.022_bb0805","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1528-1167.2011.03131.x","article-title":"The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy","volume":"52","author":"Heo","year":"2011","journal-title":"Epilepsia"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912012000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912012000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:37:37Z","timestamp":1757864257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912012000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":161,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0009912012000513"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.01.022","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}